A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

COVID-19 Updates: COVID-19 Resources » Vaccine Update » Updated Visitor Policy » What We're Doing to Keep You Safe »

CLINICAL TRIALS

About Clinical Trials Find a Clinical Trial

CLINICAL TRIALS

About Clinical Trials Find a Clinical Trial

Trial ID or NCT#

NCT01604863

Status

NOT RECRUITING

Purpose

The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or docetaxel.

Official Title

Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Inclusion Criteria:

- Have a histological or cytological diagnosis of malignant solid neoplasm requiring systemic chemotherapy. - Age ≥18 years. - ECOG performance status 0-1. - Adequate organ function. - Adequate hematological function. - Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures. - Consent to collection of previously obtained, archival biopsy or surgical specimens of the currently treated malignancy when available.

Exclusion Criteria:

- Significant cardiac disease. - Eye trauma or disease. - Ocular surgery or blunt force trauma to the eye requiring treatment within 3 months prior to first dose of HGS1036. - Presence or history of ≥ Grade 2 hemoptysis within 2 weeks of the first dose of HGS1036. - Major surgery within 4 weeks of the first dose of HGS1036. - Prior organ or allogeneic stem cell transplant. - Non-healing or chronic wounds. - Receipt of any anti-cancer therapy within 4 weeks prior to first dose of HGS1036. - Receipt of any biological therapy (such as monoclonal antibodies) within 6 weeks of the first dose of HGS1036. - Active CNS involvement by primary or metastatic tumor. - Documented active infection requiring the use of systemic antibiotics. - Pregnancy or lactation. - Known HIV-positive serology, AIDS, or an AIDS-related illness. - Conditions likely to increase the potential for abdominal perforation or fistula formation.

View All Criteria

Investigator(s)

Joel Neal, MD, PhD

Medical oncologist, Thoracic specialist

Associate Professor of Medicine (Oncology)

Heather Wakelee

Medical oncologist, Thoracic specialist

Professor of Medicine (Oncology)

Mark Pegram

Medical oncologist, Breast specialist

Susy Yuan-Huey Hung Professor

Nelson Teng

Jonathan S. Berek, MD, MMSc

Gynecologic oncologist

Laurie Kraus Lacob Professor

George A. Fisher Jr.

Medical oncologist, Gastrointestinal specialist

Colleen Haas Chair in the School of Medicine

CONTACT

Jennifer Vargas
650-723-0371

SEND MESSAGE

View on ClinicalTrials.gov

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Trial ID or NCT#

Status

Purpose

Official Title

Eligibility Criteria

Investigator(s)

CONTACT

About this Clinical Trial

Your Message Will Go To

To:

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Trial ID or NCT#

Status

Purpose

Official Title

Eligibility Criteria

Investigator(s)

CONTACT

About this Clinical Trial

Your Message Will Go To

To: